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1. Introduction  
1.1 Introduction on Lysosomal Storage Diseases (LSDs): Focus on several 
neuronopathic LSDs  
Lysosomal storage diseases (LSD) are monogenic inherited metabolic disorders, most of 
which are caused by the deficiency of a lysosomal enzyme. The deficient proteins may be 
hydrolases or cofactors involved in the degradation of macromolecules or transporters, 
which deliver catabolic products to the cytosol. Most of lysosomal enzymes are 
exohydrolases acting in sequence, such that substrates are degraded by a stepwise removal 
of terminal residues. Thus, the deficiency of a single enzyme causes the blockage of the 
entire pathway, since the failure to remove a terminal residue makes the substrate 
inaccessible for further hydrolysis by other lysosomal enzymes. The lysosomal storage 
diseases can be classified depending on the pathway affected and the nature of the 
accumulated substrate. Eleven different deficiencies can affect the degradation of 
mucopolysaccharides (mucopolysaccharidoses), nine defects are known in the degradation 
pathways of glycoproteins, one for the intralysosomal storage of glycogen (glycogenesis), 
twelve different ceroid lipofuscinoses are known, and twelve deficiencies affect 
sphingolipid catabolism (lipidoses). However, there are frequent overlaps of storage 
material between those groups. Many lysosomal hydrolases are not specific for a particular 
compound, but rather for a terminal residue, which may be identical in, e.g., gangliosides 
and glycoproteins, so that both compounds accumulate when a commonly required enzyme 
is deficient.  
Almost all lysosomal storage diseases show clinical variability. Most diseases vary with 
respect to the age at onset and progression of the symptoms. The later a disease begins the 
more protracted is the development of symptoms. Frequently, three different types of 
disease are distinguished, severe infantile, intermediate juvenile and mild adult forms, 
respectively. Although such a classification is useful, it should be realized that the spectrum 
of clinical severity is a continuum, and such imposed distinctions are artificial. In many 
lysosomal disorders symptoms, the early and late onset forms are similar, but in some 
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diseases, defects in the same gene may cause very different phenotypes. For example, beta-
o-galactosidase deficiency can cause either GM1 gangliosidosis or Morquio type B disease. 
Whereas in GM1 gangliosidosis neurologic degeneration is the major symptom, patients 
with Morquio Type B disease have no neurologic involvement, but display severe skeletal 
dysplasias. Similarly, several Gaucher disease forms (neuropathic - also called 
neuronopathic - and non neuronopathic) are distinguished depending if there is impairment 
of the central nervous system. This chapter will focus on some LSDs with neurological 
involvement, including several lipidoses and mucopolysaccharidoses. Other neuronopathic 
LSDs exist, such as the Ceroid Lipofuscinoses family, but will not be presented in this 
chapter. 
1.2 Lipidoses with neurological involvement: Biochemistry, clinical features and 
genetics  
1.2.1 GM1 gangliosidoses 
Deficiency of the enzyme beta-D-galactosidase can cause very different clinical phenotypes, 
beta-o-galactosidase hydrolyses beta-glycosidically linked terminal galactose residues from 
a variety of different substrates. These substrates are lipids such as GM1 ganglioside 
(Norden et al., 1974), oligosaccharides with terminal galactose (O'Brien, 1989; Ying and 
Wolfe, 1975) or galactose containing intermediates of the degradation of the 
mucopolysaccharide keratan sulfate (O'Brien, 1989; Tsay and Dawson, 1973). A complete 
deficiency of the enzyme results in the storage of all substrates [O'Brien, 1989; Ying and 
Wolfe, 1975; Tsay and Dawson, 1973). Accordingly, GM1 gangliosidosis presents clinical 
neurologic symptoms, which can be attributed to the storage of GM1 ganglioside in 
neurons, while storage of keratan sulfate catabolic intermediates in the viscera results in 
hepatosplenomegaly and severe bone deformities typical for mucopolysaccharidoses. The 
GM1 gangliosidosis may occur as a severe rapidly progressing infantile disease in which the 
neurologic symptoms dominate the clinical picture, but skeletal deformities, edema, 
hepatomegaly and coarse facial features are also present (O'Brien, 1989). The adult form of 
GM1 gangliosidosis shows mild, slowly progressing neurologic involvement like 
dysarthrias or gait disturbances and, except for vertebral dysplasias, little involvement of 
the skeleton (O'Brien, 1989). The beta-D-galactosidase cDNA (Oshima et al., 1988) and the 
gene (Morreau et al., 1991) have been cloned and a variety of mutations have been 
characterized. Defective alleles are heterogeneous and no single mutation with a particular 
high frequency has been found. 
1.2.2 GM2 gangliosidoses 
This group of diseases is characterized by storage of GM2 ganglioside (Sandhoff et al., 1989). 
Three polypeptide chains encoded by three different genes are involved in the degradation 
of GM2 ganglioside. The synthesis of an alpha and beta subunit for hexosaminidase (beta-N-
acetyl-D-hexosaminidase) allows for the formation of three isoenzymes alpha-alpha, alpha-
beta, beta-beta, which are designated hexosaminidase S, A, and B (Sandhoff et al., 1989). In 
order to be hydrolysed by hexosaminidase A, the ganglioside has to be associated with a 
third polypeptide, the GM2 activator protein, which solubilises the substrate for the action 
of the enzyme (Meier et al., 1991; Conzelmann and Sandhoff, 1979). The storage of GM2 
ganglioside can therefore be due to mutations in three different genes: (1) the 
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hexosaminidase alpha-subunit gene, which causes classical Tay Sachs disease or late onset 
GM2 gangliosidosis (variant B); (2) the beta-subunit gene, which causes early or late onset 
Sandhoff disease (variant 0); and (3) the GM2 activator protein (variant AB) (Sandhoff et al., 
1989). These variant forms of disease are clinically similar, but differ in the composition of 
compounds which, in addition to GM2 gangliosides, are also found in the storage material. 
The presence of additional compounds is due to the fact that GM2 ganglioside is not the 
only substrate of hexosaminidase A, and that the isoenzymes differ in their substrate 
specificities and dependence on the presence of the GM2 activator protein. Since all variant 
forms of disease are similar, the symptoms seem to be mainly due to the storage of GM2 
ganglioside and not that of other compounds.  
Classical Tay Sachs disease is characterized by a rapidly progressing neurological 
degeneration. The disease starts in between 3 to 5 months of age with progressive weakness 
and hyperirritability. A macular cherry red spot is seen in all Tay Sachs patients. 
Progression of neurologic symptoms leads to the decerebrate, vegetative state in the second 
to fourth year of life (Sandhoff et al., 1989). In the juvenile form, disease onset occurs later 
and disease progression is slower. Adult GM2 gangliosidosis represents the mildest form of 
the disease, displaying neurologic symptoms of spinocerebellar and lower motor neuron 
origin, like ataxias, dysarthrias and muscle weakness. Psychiatric symptoms are frequently 
present. A particular variant, which has been termed chronic, starts in between the age of 2 
and 5, but patients survive well into adulthood (Sandhoff et al., 1989).  
Tay Sachs disease is most prevalent in the Ashkenazi Jewish population. Three defective 
hexosaminidase alpha subunit alleles account for 93% of all mutant alleles in this ethnic 
group (Paw et al., 1990). Two other ethnic groups, both descendants from French settlers, 
have a high incidence of Tay Sachs disease. One is the Cajun community in southwest 
Louisiana, in whom the 4 bp insertion in exon 11 was found in 11 of 12 mutant alleles 
examined (McDowell et al., 1992). The other group concerns French Canadians, in which a 
7.6 kb deletion in the 5' region of the gene, which has occurred by illegitimate recombination 
between Alu repeats, accounts for more than 80% of defective alleles (Myerowitz and 
Hogikyan, 1987; Hechtman et al., 1990). Enzyme deficiencies, which do not cause disease, 
have been termed pseudodeficiencies. Pseudodeficiencies are without clinical consequences 
for the carriers, but cause problems in the diagnosis and genetic counselling. 
In Sandhoff disease, the beta-subunit deficiency causes the loss of isoenzymes A and B. The 
clinical phenotype and heterogeneity is similar to that found in Tay Sachs disease. The 
cDNA (O'Dowd et al., 1985) and the gene of the beta-subunit of hexosaminidase have been 
cloned (Proia, 1988; Neote et al., 1988). The disease is rare, but there are some demographic 
isolates with a high frequency, e.g. in a region around the town of Cordoba in Argentina 
(Brown et al., 1992). The most frequent defect found in the beta chain gene is a 16 kb 
deletion that removes the promoter and exons 1 to 5.  Homozygosity of the allele causes the 
severe late infantile form of the disease (Neote et al., 1990). As in Tay Sachs disease the 
milder forms have been found to be associated with mutations leading to the synthesis of 
enzymes displaying some residual activity (Bolhuis et al., 1993). 
The third polypeptide involved in the degradation of GM2 ganglioside is the GM2 activator 
protein. The deficiency of this protein is rare and causes a disease that is clinically similar to 
Tay Sachs disease. This small 24 kDa protein interacts with the alpha-subunit of the 
hexosaminidase isoenzyme A (Kytzia and Sandhoff, 1985) and solubilizes lipids such as 
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GM2 ganglioside or GA2 glycolipid for the hydrolysis by hexosaminidase A (Conzelmann 
and Sandhoff, 1979). The cDNA and gene of this protein have been cloned (Klima et al., 
1991), and five mutations have been described so far. 
1.2.3 Niemann Pick disease 
Niemann Pick disease type A and B are caused by a deficiency of the enzyme acid 
sphingomyelinase (Spence and Callahan, 1989). This enzyme hydrolyses sphingomyelin into 
ceramide and phosphorylcholine. Deficiency of the lysosomal enzyme causes storage of 
sphingomyelin (Spence and Callahan, 1989). Two types of disease can be distinguished an 
acute type A and a chronic type B disease. The acute form is a severe disorder of infancy 
characterized by progressive psychomoter retardation, massive visceromegaly and death by 
3 years of age. The chronic form is characterized by a visceromegaly, but little involvement 
of the nervous system and survival into adulthood. Accordingly, the two types of disease 
are termed neuronopathic (type A) and nonneuronopathic (type B). The disease is 
panethnic, but has a higher frequency among Ashkenazi Jews. The cDNA (Quintern et al., 
1991) and the gene (Schuchman et al., 1992) of sphingomyelinase have been cloned. Three 
mutant alleles have been found to be most frequent among Ashkenazi Jews. 
In addition to Niemann Pick type A and B there is a third clinically similar form termed type 
C. Cells from these patients show an impaired intracellular transport of cholesterol from 
lysosomes, but the primary defect is not in the sphingomyelinase gene and has so far not 
been elucidated. 
1.2.4 Metachromatic leukodystrophy 
The deficiency of arylsulfatase A causes metachromatic leukodystrophy. The substrate of 
this enzyme is cerebroside-3-sulfate (sulfatide). This glycolipid is mainly found in the 
myelin sheaths of the nervous system. Deficiency of arylsulfatase A causes storage of 
sulfatide in various organs, but the disease mainly affects the nervous system (Kolodny, 
1989). Patients suffer from progressive demyelination, which leads to a variety of neurologic 
symptoms and finally causes death. Typically the disease starts with gait disturbances at the 
age of 18 to 24 months, in the further course of disease patients develop a spastic 
tetraparesis, seizures and dementia. In the milder late onset forms psychiatric symptoms 
frequently prevail initially before neurologic symptoms become apparent (Kolodny, 1989). 
Arylsulfatase A is encoded in a small gene (Kreysing et al., 1990), and the entire coding 
sequence of 1.5 kb is distributed over 8 exons and encompasses not more than 3 kb of 
genomic sequence. Two mutant alleles are particularly frequent and account each for about 
25% of mutant alleles among Caucasian patients (Polten et al., 1991; Barth et al., 1993).  
Deficiency of arylsulfatase A has also been demonstrated in healthy individuals at high 
frequency (up to 2.6% of the population) (Barth et al., 1993; Hohenschutz et al., 1989). The 
deficiency is substantial, but since it is not complete it does not cause a disease and is 
another example of lysosomal enzyme pseudodeficiency (Dubois et al., 1977).  
1.2.5 Gaucher disease (neuronopathic) 
Gaucher disease is caused by the deficiency of beta-0-glucocerebrosidase (Brady et al., 1965). 
The enzyme hydrolyses glucose from the sphingolipid glucosylceramide (Brady et al., 1965). 
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Glucosylceramide is an intermediate compound in the synthesis and degradation of 
complex glycosphingolipids. Deficiency of the enzyme causes storage of glucosylceramide 
mainly in cells of the monocyte/macrophage system (Grabowski, 1993). Generally, Gaucher 
disease affects the bone marrow, bone, spleen, and liver, causing anaemia, 
thrombocytopenia, bone lesions and hepatosplenomegaly. In the less frequent, more severe 
forms of the disease, the central nervous system is also affected and, as in Niemann Pick 
disease, these variants have been termed neuronopathic. 
The severe neuronopathic form (type II Gaucher disease) is rare and occurs panethnically, 
i.e. without any ethnic distinction. It presents hepatosplenomegaly and neuronal 
complications (Grabowski, 1993). The clinical presentation is quite uniform and death 
usually occurs before 2 years of age.  
The mild nonneuronopathic form (type I disease) is frequent among Ashkenazi Jews and is 
clinically heterogeneous. A third intermediate form of Gaucher disease (type III) is a so 
called “subacute neuronopathic form”, which, due to its high frequency in a Swedish isolate, 
has also been termed Norbottnian type Gaucher disease (Dahl et al., 1990). Patients show 
neuronal as well as visceral involvement, but the neurological symptoms develop later and 
more slowly than in the acute neuronopathic form.  
The cDNA, the gene and pseudogene of beta-D-glucocerebrosidase have been cloned (Sorge 
et al., 1985; Horowitz et al., 1989). The pseudogene is tightly linked to the normal gene, but 
is smaller due to several mainly intronic deletions. At least 200 different mutations have 
been characterized (Pastores et al., 2000). Most of these mutations are rare and some are 
limited to single families. However, five of the mutant alleles account for more than 98% of 
defective beta-D-glucocerebrosidase alleles among Ashkenazi and for about 70% of mutant 
alleles among non Jews (Beutler, 1993; Horowitz et al., 1993). 
1.2.6 Krabbe disease 
Krabbe disease or globoid cell leukodystrophy is due to the deficiency of beta-D-
galactocerebrosidase (Suzuki and Suzuki, 1989). The enzyme releases galactose from 
galactocerebroside, one of the major membrane lipids of the myelin sheaths. Like in 
metachromatic leukodystrophy patients suffer exclusively from neurologic symptoms 
(Suzuki and Suzuki, 1989). In the first six months of life, they display hyperirritability 
towards external stimuli, hyperaesthesia, spasticity and regression of neurologic 
development. Patients usually die before their second year of life in a decerebrate state 
(Suzuki and Suzuki, 1989). In addition late onset forms have been described. The cloning of 
the gene has been difficult due to the low abundance and hydrophobicity of the enzyme, but 
has recently been achieved (Chen et al., 1996; Sakai, 1994). The purified enzyme has a 
molecular weight of 51 kDa. The cloned cDNA has 3795 nucleotides, of which 2007 
nucleotides represent an open reading frame, predicting a 669 amino acids protein (Chen et 
al., 1996). Although the substrates of beta-D-glucocerebrosidase and beta-D-
galactocerebrosidase are structurally similar, no sequence homology between the two 
enzymes has been found. A nonsense mutation was found at codon 369 (GAA > TAA) in the 
coding sequence of cDNA amplified from cultured skin fibroblast mRNA from a patient 
with typical Krabbe disease (Sakai, 1994).  
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1.3 Mucopolysaccharidoses with neurological involvement: Biochemistry, clinical 
features and genetics 
Mucopolysaccharidoses (MPS) are a subgroup of lysosomal storage diseases caused by a 
deficiency in specific acid hydrolases responsible for the degradation of complex 
glycosaminoglycans (GAGs) (Neufeld and Muenzer, 2001), which causes substrate 
accumulation within the lysosomes of the cells of the central nervous system (CNS) and of 
other organs. As already stated, only the MPS which display neurological traits will be 
described here. This concerns MPS types I, II, III and VII. Patients with neurologic MPS 
share several clinical signs, including a severe neurodeterioration and systemic symptoms. 
1.3.1 Mucopolysaccharidosis type I 
Mucopolysaccharidosis type I (MPS I) is caused by the deficiency of alpha-L-iduronidase. 
This enzyme cleaves terminal iduronic acid residues from the glycosaminoglycans heparan 
and dermatan sulfate (Neufeld and Muenzer, 2001). Deficiency causes storage and urinary 
excretion of undegraded or partially degraded heparan and dermatan sulfate 
mucopolysaccharides (Neufeld and Muenzer, 2001). The spectrum of clinical phenotypes is 
broad. In the severe form, patients typically show symptoms in the first year of life 
presenting with hepatosplenomegaly, skeletal dysplasias, corneal clouding, short stature 
and mental retardation. These severe forms have been termed Hurler syndrome. At the 
other end of the clinical spectrum are the patients with mild form of disease termed Scheie 
syndrome. They have little or no neurologic involvement, have mild hepatosplenomegaly, 
joint stiffness and deformities, heart valve problems, but may have a normal lifespan. 
Intermediate phenotypes have accordingly been termed Hurler/Scheie syndrome (Neufeld 
and Muenzer, 2001).  
The cDNA and the gene of the a-L-iduronidase have been cloned (Scott et al., 1991; Scott et 
al., 1992). The emerging pattern of genotype-phenotype correlation in MPS I ressembles that 
of other lysosomal storage diseases, in so that homozygosity for null alleles causes severe 
disease and alleles associated with some residual activity allow for a milder course of the 
disease. 
1.3.2 Mucopolysaccharidosis type II 
Mucopolysaccharidosis type II (MPS II) is caused by the deficiency of alpha-L-iduronate-2-
sulfate sulfatase. The enzyme desulfates iduronate-2-sulfate residues, which can be found in 
heparan and dermatan sulfate. Deficiency of the enzyme causes accumulation of 
degradation intermediates (Neufeld and Muenzer, 2001). MPS II is the only 
mucopolysaccharidosis that is inherited as an X linked trait. Clinically, it resembles MPS I, 
with skeletal abnormalities, hepatosplenomegaly, but less severe mental retardation and no 
corneal clouding. The spectrum of clinical severity is broad, alpha-L-iduronate- 2-sulfate 
sulfatase cDNA has been cloned and the structure of the gene has been determined (Wilson 
et al., 1990; Wilson et al., 1993). The cDNA sequence predicts a protein of 550 amino acids 
and the deduced amino acid sequence shows a strong homology to other lysosomal and non 
lysosomal sulfatases. The gene seems to be prone to deletions, which have been detected in 
about every fourth patient (Wilson et al., 1991; Palmieri et al., 1992). Complete deletions of 
the gene can be found in 8% of patients (Bunge et al., 1992), and those always suffer from the 
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most severe type of MPS II as do patients with other gross rearrangements. At least thirty 
one point mutations have been described which cause severe, intermediate or mild type of 
disease. 
1.3.3 Mucopolysaccharidosis type III 
The MPS type III syndrome (Sanfilippo syndrome) is an inherited autosomal recessive 
lysosomal storage disease resulting from deficiency in the enzyme sulfamidase (SGSH) for 
the MPS IIIA type, in the alpha-N-acetylglucosaminidase (NAGLU) for the MPS IIIB type, in 
the alpha-glucosaminide N-acetyltransferase for the MPS IIIC type, and in the N-
acetylglucosamine 6-sulfatase for the MPS III D type. These enzymes participate to the 
sequential degradation of heparan sulphate (one of the major glycosaminoglycan) (Neufeld 
and Muenzer, 2001). The MPS III disease, which is one of the most frequent MPS, is 
characterized by severe central nervous system degeneration, resulting in progressive 
mental retardation for the most severe forms. After a period of seemingly normal 
development, patients exhibit a range of symptoms, including rapid loss of social skills with 
hyperactivity and aggressive behaviour, loss of learning ability, disturbed sleep patterns, 
hirsutism, coarse facies, and diarrhea. Fatal issue occurs in severely affected children in the 
mid- to late-teenage years, usually as a result of respiratory infection (Cleary and Wraith, 
1993).  
A total of 62 mutations have now been defined for MPS IIIA, the most frequent MPS III, 
consisting of 46 missense/nonsense mutations, 15 small insertions/deletions, and one splice 
site mutation. A total of 86 mutations have been identified in the NAGLU gene of MPS IIIB 
patients; 58 missense/nonsense mutations, 27 insertions/deletions, and one splice site 
mutation. Most of the identified mutations in the SGSH and NAGLU genes are associated 
with severe clinical phenotypes. Many of the missense, nonsense, and insertion/deletion 
mutations have been expressed in mammalian cell lines to permit the characterization of 
their effects on SGSH and NAGLU activity and intracellular processing and trafficking 
(Yogalingam and Hopwood, 2001). 
1.3.4 Mucopolysaccharidosis type VII  
Mucopolysaccharidosis VII (MPS VII) is caused by the deficiency of the enzyme beta-D-
glucuronidase (GUS). This enzyme hydrolyses terminal glucuronic acid residues from 
glycosaminoglycans dermatan and heparan sulfate, chondroitin- 4 and -6 sulfate (Neufeld 
and Muenzer, 2001). The clinical picture shows a wide spectrum of severity and resembles 
that of MPS I and MPS II. Patients suffer from skeletal dysplasias, hepatosplenomegaly, and 
moderate mental retardation. Intelligence can be normal in late onset cases (Neufeld and 
Muenzer, 2001). In addition a severe neonatal form of MPS VII exists, which is already 
present during pregnancy as a hydrops fetalis (Wu and Sly, 1993). The cDNA (Oshima et al., 
1987) and the beta-D-glucuronidase gene have been cloned (Miller et al., 1990). So far, 49 
unique disease-causing mutations were determined in the GUS gene, including nine novel 
mutations (eight missense and one splice-site). This heterogeneity in GUS gene mutations 
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1.4 Pathophysiology, central nervous system and blood brain barrier issues 
1.4.1 Pathophysiology 
A lysosomal defect leads to the accumulation of undegraded material, thus causing cell and 
organ dysfunction. Many investigations in a great number of tissues and organs have been 
carried out over the years, in order to explain how substrate accumulation results in disease. 
From these studies it has been realized that there are many factors playing a role in the 
pathophysiology of lysosomal storage disorders. For example, it is well known that, in 
Gaucher disease, the macrophages, which are activated by the storage of glucosylceramide, 
release a large number of cytokines or chemokines that have inflammatory effects (Hollak et 
al., 1997). Other investigations have provided evidence that inflammatory processes also 
contribute significantly to neurodegeneration in gangliosidoses. The report by Wada et al. 
(2000) demonstrated macrophage/microglial activation in the brain of a Sandhoff mouse 
model and in human Sandhoff brain implicating a neuro-inflammatory component in this 
disorder. In addition, Jeyakumar et al. (2003) has analysed the expression of inflammatory 
markers in mouse models of GM2- and GM1-gangliosidosis and found a significant 
elevation of MHC class II, CD68, CD4, CD8 and of cytokine production in the brain of 
affected animals. The observation that the increase of these mediators was accompanied by 
progressive microglial activation and expansion supports the hypothesis that inflammation 
is the major cause of neurodegeneration in gangliosidoses. This microglial activation is a 
characteristic shared by numerous neurodegenerative diseases (Minagar et al., 2002) and 
other lysosomal diseases, such as MPS I, MPS IIIB (Ohmi et al., 2003), Niemann-Pick type C 
(German et al., 2002), Krabbe disease (Wu et al., 2000), MPS VII (Richard et al., 2008) and 
MPS IIIA (Arfi et al., 2011). 
Astrocytosis, like microglial activation, has also been widely described in neurodegenerative 
disorders (Wu and Proia, 2004; Tsuji et al., 2005; Arfi et al., 2011) and could be triggered by 
the release from activated macrophages of several cytokines and neurotrophic factors, such 
as MIP1α and IL1β (Giulian et al., 1988,Wang and Shuaib, 2002). 
An inflammatory process also seems to play a role in the development of joint and bone 
disease in mucopolysaccharidoses. Simonaro et al. (2005) showed that connective tissue cells 
are stimulated by inflammatory cytokines and nitrite oxide in animal models of MPS VII, 
analogous to the situation in arthritis. The brain of patients with neuronopathic forms of 
Gaucher disease contain not only an increased concentration of glucosylceramide, but also 
of glycosylsphingosine (glucosylceramide devoid of the N-acetylated fatty acid) (Orvisky et 
al., 2000).  Glycosylsphingosine is known to be toxic to cells, and was therefore suggested to 
be the primary cause of the pathology (Orvisky et al., 2000). However, according to the work 
of Pelled et al. (2000) in post-mortem human brain from Gaucher disease patients, the level 
of glycosylsphingosine does not appear to be high enough to explain the involvement of 
central nervous system in type II and type III Gaucher disease. In the same study, the 
authors demonstrated that in the microsomal fraction of the patient’s brain agonist-induced 
calcium release was significantly enhanced, as compared to control brains. Since elevated 
Ca++ results in enhanced sensitivity to agents that induce cell death and apoptosis, it has 
been suggested that disturbance of calcium homeostasis may be a significant mechanism 
responsible for neuropathophysiology in acute neuronopathic Gaucher disease. Also, in 
animals affected by Gaucher, Sandhoff or Niemann–Pick diseases, a defective regulation of 
intracellular calcium has been shown to be an important pathogenic factor (Ginzburg et al. 
2004; Arfi et al., 2006).  
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Furthermore, a clear oxidative stress was observed in several neurological lysosomal storage 
diseases. Other studies previously highlighted the realease of reactive oxygen species (ROS) 
and/or the increased expression of components of the phagocyte NADPH oxidase in GM1 
gangliosidosis (Jeyakumar et al., 2003), MPS IIIB (Villani et al., 2007), MPS I (Reolon et al., 
2009), Batten disease (Benedict et al., 2007), or MPS IIIA (Arfi et al., 2011). It is still not 
defined whether the previously reported and presently observed oxidative imbalance is 
triggered by lysosomal dysfunction (Butler and Bahr, 2006), by autophagy impairment as 
recently described in MPS IIIA and Multiple Sulfatase Deficiency mouse models (Settembre 
et al., 2008), or is a secondary result from microglial activation. Nevertheless, it seems clear 
that these oxidative alterations may enhance damages in the brain cells, and may contribute 
to cognitive impairment as well as neurodegeneration through decline in synaptic integrity.  
In summary, although we presently do not completely understand the pathophysiology of 
lysosomal storage disorders, there is no doubt that accumulation of storage material is the 
first pathogenic factor which triggers secondary structural and biochemical alterations, 
thereby leading to disease initiation and progression. Removal of this toxic storage material 
should be the first therapeutic goal. 
1.4.2 Turnover and trafficking of lysosomal enzymes in the central nervous system  
The lysosomal storage diseases (LSDs) affecting the central nervous system (CNS) pose the 
greatest challenges in treatment. An understanding of lysosomal enzyme transfer in the 
CNS, and how this is perturbed in these disorders, is therefore essential to successful 
treatment, and merits separate consideration.  
Microglia represents the resident brain population of macrophages (van Furth et al., 1972; 
Naito et al., 1996). Microglial cells have many characteristics of macrophages, including the 
presence of hydrolases (Ling, 1977). They are derived from circulating blood monocytes that 
invade the brain early in postnatal life and become amoeboid microglia, which then 
differentiate into ramified microglia. Postnatally, microglial cells are continuously replaced 
by blood-bone monocytes that cross the blood–brain barrier (BBB) into the brain 
parenchyma. As they contain acid hydrolases, it has been postulated that the secretion-
uptake machinery applies to microglia and the surrounding neurones. That is to say, a 
proportion of lysosomal enzymes is secreted out of microglia and is available for recapture 
by the surrounding neurones. Direct experimental evidence of neuronal uptake of lysosomal 
enzymes has been shown by the reversal of storage in neural cells surrounding a graft of 
genetically corrected fibroblasts in the mucopolysaccharidoses VII (MPS VII) mouse brain 
(Taylor & Wolfe, 1997). A gene therapy strategy also showed neuronal uptake, using a 
lentiviral vector in murine embryonic Sandhoff neurons (Arfi et al., 2006).  
However, local secretion and uptake of lysosomal enzymes is not their only mode of 
transfer in the CNS. Axonal transport also occurs (Passini et al., 2002) and is probably an 
important mechanism for transfer to distant sites. Exactly what proportion of secreted 
lysosomal enzyme undergoes axonal transport is not known. However, it is a potentially 
important therapeutic route. 
The origin of the substrate may differ inside and outside the CNS. This may explain why 
some patients with a similar enzyme deficiency have neurological involvement while others 
do not. Gaucher’s disease is a good example of this. Patients with type I Gaucher’s disease, 
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do not have neurological involvement (non-neuronopathic), while patients with types II and 
III do (neuronopathic). Patients with the neuronopathic forms of Gaucher’s disease have 
increased levels of the substrate glucosylceramide (GCS) in the brain. Glucosylceramide is 
derived from two sources. Inside the CNS it is derived predominantly from gangliosides, 
while elsewhere it is derived predominantly from the breakdown of blood cells. In type I 
patients, the degradation of blood cell derived glucosylceramide is blocked, but there is 
sufficient enzyme activity in the CNS to break down ganglioside-derived glucosylceramide, 
thus preventing its accumulation in the brain (Brady et al., 1993). In types II and III, 
however, there is less residual lysosomal enzyme activity (Brady, 1966), which is insufficient 
to degrade ganglioside-derived GCS in the CNS (Brady et al., 1965, 1993; Zhao et al., 2003).  
1.4.3 The blood-brain-barrier (BBB) 
The delivery of many potentially therapeutic and diagnostic compounds to specific areas of 
the brain is restricted by the blood-brain barrier, the blood-CSF barrier, or other specialised 
central nervous system (CNS) barriers. These brain barriers are now recognised as a major 
obstacle to the treatment of most brain disorders.  The blood-brain barrier (BBB) is 
constituted by the endothelial cells of the brain capillaries. These cells are linked by tight 
junctions that form an effective barrier to paracellular aqueous diffusion (Brightman & 
Reese, 1969; Kniesel & Wolburg, 2000). Such junctions do not exist in the capillary 
endothelial cells of the peripheral circulation. This difference is thought to be the result of 
close apposition to both astrocytes and pericytes, both of which are tightly applied to the 
basement membrane of the cerebral capillaries (Kacem et al., 1998). Astrocytes have end feet, 
which spread in a network around the capillaries. The BBB also forms an electrical barrier in 
the form of a transendothelial electrical resistance (Begley & Brightman, 2003).  
It can be readily seen, therefore, that the BBB effectively prevents most polar bloodborne 
solutes from crossing. Yet monocytes cross the BBB and differentiate into microglia. 
Migration is significantly inhibited by the addition of blocking antibodies to intercellular 
adhesion molecule-1, very late antigen-4 integrin, and monocyte chemoattractant protein 
(CCL-2/MCP-1), or treatment with tissue inhibitor of metalloproteinase (Seguin et al., 2003). 
These results support the concept that monocyte–endothelial cell interactions are somehow 
responsible for monocyte migration across the BBB.  
2. Therapeutic strategy which aims at restoring enzyme activity  
Until now, no treatment is available for patients with neurological lysosomal storage 
diseases (LSDs), leading to the only option of prenatal diagnosis for high-risk families, thus 
avoiding the birth of diseased children. The families, who do not have this option, have to 
overcome the fatality of a rapid death of their children.  
The availability of relevant animal models of these diseases has enabled the development of 
innovative therapeutic approaches. The orphan medicine status for these pathologies has 
interested a few biopharmaceutical and biotechnologies companies. Previously, substitutive 
therapies, allowing enzymatic restoration have been developed and successfully used in 
patients with Gaucher or Fabry diseases, as well as several MPS. Other strategies can also be 
imagined, such as the use of chaperone molecules, bone marrow transplantation, as well as 
gene and cell therapies.  
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Depending on the enzymatic default, different approaches can be put in place: either the 
provision of the missing enzyme or the protein stabilization if the deficiency is due to a 
default in the protein stability. Other approaches can facilitate the provision of exogenous 
enzyme and are based on the secretion-uptake capacity of lysosomal enzymes, in order to 
obtain a trans-correction of deficient cells. Another major argument is the assumption that a 
partial correction (5-10%) could be enough to sustain a normal phenotype. This idea is based 
on pseudodeficiencies: some patients, who do not have any clinical symptom, have an 
enzymatic activity collapsed at 10% of the normal activity (Cao et al., 1997; Leinekugel et al., 
1992).  
2.1 Enzyme replacement therapy 
Enzyme replacement therapy (ERT) is certainly the earliest therapeutic approach which has 
been successful in lysosomal storage diseases (LSDs) at the clinical level. De Duve, in 1964, 
was the first to suggest the concept of exogenous enzyme supplementation (de Duve, 1964).  
The first clinical trials were performed in the 1970s, using intravenous injections of human 
protein. Rapidly, the investigators realised that the central nervous system (CNS) would be 
difficult to reach, due to the blood brain barrier. Thus, they focused on non-neurologic 
LSDs.  
Roscoe Brady developped the ERT for Gaucher type I disease. In the early 1990s, the first 
results showed that one weekly infusion of 2 to 3 mg/kg enzyme modified in its 
glycosylation, could lead to a significant reduction of the substrates accumulation and to the 
disappearance of clinical symptoms (Barton et al., 1990). These trials were sponsored by a 
biotechnologies company, Genzyme, and led to a marketing authorization in 1991 in 
Europe, Israel and USA.  
The recent development of molecular biology and the cloning of cDNA of main lysosomal 
hydrolases, have led to the large-scale production of the recombinant protein. The 
generation of disease mouse models by homologous recombination allowed ERT test in 
preclinical studies. Thanks to these technological progresses, clinical trials were initiated by 
three biopharmaceutical companies: Genzyme®, BioMarin Pharmaceutical Inc, and 
Transkaryotic Therapies (now Shire Pharmaceuticals), for several disorders such as Fabry 
disease, mucopolysaccharidoses (MPS) I, II, VI, and Pompe disease, leading to the 
commercialization of a therapy for these diseases, improving most of the peripheric 
symptoms in these disorders . For example, the Food and Drug Administration (FDA) has 
approved the orphan medicine Aldurazyme® (Laronidase) in May 2003, for the treatment of 
certain forms of mucopolysaccharidosis type I (MPS I). Aldurazyme® is a version of the 
human form of the enzyme alpha-L-iduronidase. Treated patients exhibited significant 
improvements in their lung function and their ability to walk. At the molecular level, 
Aldurazyme® reduced carbohydrates accumulation (FDA Talk Paper, 2003).  
For several years, enzyme replacement therapy (ERT) based on intravenous injection of 
recombinant enzyme, whose deficiency causes the disease, has been used to treat MPS I 
(Kakkis et al., 2001; Wraith et al., 2004), MPS II, and MPS VI (Muenzer et al., 2002; Harmatz 
et al., 2006; Muenzer et al., 2006), and it appears that an analogous therapy could be also 
efficient for MPS IVA (clinical trial on going) (Tomatsu et al., 2008; Dvorak-Ewell et al., 
2010). This therapy is effective for treating somatic symptoms of MPS I, MPS II, and MPS VI. 
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However, intravenous administration of enzymes appears to be inefficient for CNS 
treatment because of the blood–brain barrier. 
However, over the past few years, researchers have investigated high-dose ERT in animal 
models of a number of LSD, including MPS VII (Vogler et al. 2005), Krabbe disease (Lee et 
al., 2005), metachromatic leukodystrophy (MLD; Matzner et al., 2009) and MPS IIIA 
(Rozaklis et al., 2011). With the exception of the latter study in MPS IIIA mice, these reports 
demonstrate that high dose ERT can mediate reductions in neuropathology and, in some 
cases, improve neurological function. The mechanisms by which high-dose enzyme access 
the brain are not well understood, but several hypotheses have been advanced, such as 
carriage via blood-borne macrophages, saturation of M6P receptors, and increased plasma 
half-life. 
To circumvent the BBB, the direct intracerebroventricular (i.c.v.) injection of lysosomal 
enzymes has been explored. Intrathecal enzyme replacement therapy (ERT) holds promise 
as a treatment for the central nervous system manifestations of lysosomal storage diseases, 
since treatment via the cerebrospinal fluid represents a potential method of delivering 
recombinant enzyme across the blood-brain barrier. All intra-cerebrospinal fluid ERT 
studies in mice have reported improved function, and reduced neuropathology has also 
been described in the brain of dog models (MPS I (Kakkis et al., 2004; Dickson et al., 2007), 
MPS IIIA (Hemsley et al., 2007, 2008, 2009). However, several questions remain regarding 
this approach, in particular which route of injection (ventricular, cisternal or lumbar) 
provides the most widespread distribution of enzyme in brain parenchyma; is bolus or 
sustained delivery of enzyme via an osmotic pump device preferable; and, finally, what is 
the optimal frequency of administration for each condition? This treatment approach is now 
in clinical trials (MPS I; NCT 00638547 and NCT 00852358; MPS II, NCT 00920647 and MPS 
IIIA; NCT01155778; see www. clinicaltrials.gov). 
2.2 Bone-Marrow transplantation  
Cells that are primarily involved in the systemic manifestations of many storage disorders 
are macrophages that arise from stem and progenitor cells in the bone marrow. Because of 
this etiology, bone marrow transplantation (BMT) has been tried in a number of metabolic 
disorders with varying degrees of success. If engraftment of healthy donor cells is successful 
and incapacitating graft-versus-host reactions do not occur, or if it arises and is properly 
controlled by immunosuppression, BMT can cure certain patients with type 1 Gaucher 
disease in whom the brain is not involved. However, difficulties in obtaining suitable 
donors, dangers associated with myeloablation, and the likelihood that recipients may 
require immunosuppression throughout their life raises serious concern about the 
advisability of BMT for lysosomal storage diseases diseases. 
2.3 Cell/stem cell and gene therapy 
As described above, enzyme replacement therapy has become a therapeutic option for some 
lysosomal storage disorders, but, has been shown to be of limited efficacy, especially 
regarding the effect on bone and brain manifestation. Furthermore, the recurring 
administration of an exogenous protein bears the risk of inducing an immune response that 
may interfere with the therapeutic enzyme or even neutralize its activity. Gene-based 
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therapy may overcome this problem, as it may allow constant delivery of a therapeutic 
protein to the whole body or to targeted organs, as for example the bone or the brain. For 
several reasons lysosomal storage disorders are excellent candidates for therapy by gene 
transfer (Sands and Davidson, 2006). At first, they represent generally well-characterized 
single gene disorders, secondly they are not subject to complex regulation mechanisms, and 
an enzyme activity of only 15–20% of the normal level is sufficient for clinical efficacy. There 
are two ways to deliver a gene into the organism, the in vivo and the ex vivo technique.  
2.3.1 In vivo gene therapy 
To establish a sustained source of therapeutic protein within the body for metabolic 
correction in peripheral organs, the liver has been used as a depot organ. In animal 
experiments several vehicles such as adenoviral adeno-associated, retroviral and lentiviral 
vectors were used for efficient liver transduction. By such strategies, the liver produced 
large amounts of therapeutic enzyme that was secreted into the bloodstream and recaptured 
by the target organs by the mannose-6-phosphate receptor. The efficacy of this technique 
has been demonstrated in several animal models. The team of Mango and co-workers used 
mice and dogs affected by MPS VII (beta-glucuronidase deficiency, Sly disease) for their 
experiments. Neonatal intravenous injection of a retroviral vector (RV) expressing canine 
beta-glucuronidase resulted in hepatocyte transduction, and secreted enzyme was taken up 
from blood by other organs. The treated animals did not develop major signs of the disease, 
such as cardiac abnormalities or corneal clouding and displayed significant amelioration of 
the skeletal, cartilage and synovial disease (Mango et al., 2004).  
Non viral methods were also tested by our group to target the liver of MPS VII mice, using 
hydrodynamic injections of plasmid containing the beta-glucuronidase cDNA, leading to 
improvements in both peripheral and brain manifestations of MPS VII disease (Richard et 
al., 2009). The surprising biochemical correction observed in brain, while only the liver was 
producing the enzymes in this particular study, points to the possibility of the therapeutic 
enzymes crossing the blood-brain barrier (BBB) when continuously produced at the 
periphery. Although this effect might be related to inflammation-mediated BBB leakage in 
the particular MPS VII mouse model used, these results provide a rationale and hope for the 
treatment of other neurologic LSD. 
In an alternative to the “liver” approach, Li et al. (2002) used the lung as a depot organ for 
delivering beta-galactosidase into the heart and kidney of mice affected by Fabry disease.  
Long-term analysis of several gene transfer experiments has shown the occurrence of 
immune response leading to clearance of the transduced cells and/or loss of enzyme activity 
(Di Domenico et al., 2005). However, it could be demonstrated that the immune response 
may be prevented by using hepatocyte-specific promoters that restrict transgene expression 
to parenchymal cells of the liver and avoid transgene expression within antigen-presenting 
cells (Follenzi et al., 2004).  
In spite of the results obtained on MPS VII mice by our group (Richard et al., 2009, the 
beneficial effect of gene transduction into the liver or other peripheral tissues is generally 
considered to be restricted to peripheral organs, as the secreted enzyme will not cross the 
blood brain barrier. Therefore, vector delivery systems have been developed for direct in 
vivo gene transfer into the CNS. Desmaris and co-workers injected into the brain of MPS I 
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mice a single dose of gene transfer vectors derived from adeno-associated virus (AAV) 
coding for human alpha-iduronidase. The procedure prevented the accumulation of GM2 
and GM3 gangliosides, which apparently contributes to neuropathology. Storage material, 
which already was present at the time of treatment, disappeared from both brain 
hemispheres (Desmaris et al., 2004). Similar results have been obtained by Ciron et al. (2006) 
who used MPS I dogs as an animal model. In their experiments adeno-associated virus 
vectors coding for human alpha-iduronidase was injected into the animal brain. The 
procedure prevented glycosaminoglycan accumulation and resulted in significant reduction 
of neuropathology throughout the brain. However, since deficient dogs raised antibodies 
against AAV in response to infusion, intracerebral vector injections had to be combined with 
an immunosuppressive treatment. More recently, a widespread enzymatic correction of 
CNS tissues was obtained after one single intracerebral injection of therapeutic lentiviral 
vector in leukodystrophy mouse models (Lattanzi et al., 2010). Several other teams have 
shown promising results in MPS IIIB, MPS I, MPS IIIA mouse or dog models, using either 
intracranial AAV-mediated gene therapy (Heldermon et al., 2010; Ellinwood et al., 2011; 
McIntyre et al., 2010; Fraldi et al., 2007) or intracisternal AAV gene transfer (Fu et al., 2010).   
Brooks et al. used recombinant feline immunodeficiency virus (FIV)-based vectors for 
transfer of the beta-glucuronidase gene into the brain of adult MPS VII mice. In both 
hemispheres a modest reduction of storage material or even a correction of characteristic 
cellular pathology was detected. Although the affected mice before treatment had already 
shown significant deficits in spatial learning and memory there was a dramatic functional 
improvement as a consequence of the gene therapy (Brooks et al., 2002).  
Recent studies have shown that the fusion of the lysosomal enzyme beta-glucuronidase with 
a peptide, the protein transduction domain from HIV Tat, allows for mannose-6-phosphate 
independent uptake in vitro and alters the biodistribution of the enzyme after systemic 
delivery in a mouse model for MPS VII (Orii et al., 2005). However, in the brain of the 
treated animals only a slight increase of enzyme activity was observed after intravenous 
injection of the glucuronidase-Tat chimeric protein when expressed from viral vectors (Xia 
et al., 2001). The efficacy of a therapeutic lentiviral vector was also studied in MPS IIIA 
(McIntyre et al., 2008) and in MPS IIIB mouse models (Di Domenico et al., 2009) and showed 
to have the capacity to alleviate most disease manifestations.  
Overall, gene transfer methods have shown very promising results in several neurological 
LSDs at the preclinical level. In consequence, several clinical trials (Phase I/II) have been 
launched and more are projected, as illustrated in Table 1. A phase I clinical trial in CLN2 
patients, using intracranial AAV-based gene therapy, showed no toxicity, but no efficiency 
at this stage (Souweidane et al., 2010). A Phase I/II trial for MPS IIIA patients has just been 
authorized and will assess the efficacy of several intracranial injections of a therapeutic AAV 
vector. Another clinical trial is in preparation for MPS IIIB patients. 
2.3.2 Ex vivo gene therapy and cell therapy 
Based on the positive clinical experience with bone marrow transplantation in some 
lysosomal storage disorders (LSDs), hematopoietic stem cell-mediated gene therapy was 
considered as an attractive alternative for the treatment of LSDs. Gene transfer strategies 
aimed at correcting the genetic defect in the hematopoietic stem cells may have significant 
advantages compared with conventional allogeneic stem cell transplantation. Because 
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autologous cells are used for ex vivo gene therapy, transplant-related morbidity and 
mortality are reduced as there is no risk of graft-versus-host disease. Furthermore, 
genetically modified cells may express higher levels of the therapeutic enzyme and become 
more effective than wild-type cells. 
For ex vivo therapy, stem cells of the patient are transfected with the gene and thereafter 
returned to the body. The efficacy of this procedure has been demonstrated in many 
experiments on LSD animals, for example in MPS I mice. Bone marrow from affected male 
donor mice was transduced with human iduronidase cDNA by using an MND retroviral 
vector and transplanted into 6–8 week old, lethally irradiated affected female mice. The 
procedure resulted in correction of pathology of liver, spleen, cartilage cells and even of 
kidney, choroid plexus and thalamus, as seen by light microscopy. Electron microscopy 
showed the presence of some normal neurons in the cortex. The partial correction of brain 
pathology was attributed to migration of donor hematopoietic cells, demonstrated by the 
presence of the Y chromosome and of normal microglia in the brain of mice receiving 
iduronidase cDNA (Zheng et al., 2003).  
As discussed above, microglial cells play a major role in the pathogenesis of CNS 
involvement in many lysosomal storage disorders (Ohmi et al., 2003; Wada et al., 2000). 
These cells apparently represent the primary site of lipid storage resulting in cell activating 
and secretion of cytokines and pro-inflammatory molecules that trigger the focal 
inflammation, demyelination, and neurodegenerative features of these disorders. Therefore, 
microglia should be the primary target cell type in therapeutic strategies for LSDs.  
Gene-marking studies in animal models have shown that hematopoietic stem cells 
significantly contribute to the turnover of CNS-resident microglia: hematopoietic stem cells, 
transfected with lentiviral vectors encoding the green Fluorescent protein (GFP), were 
extensively engrafted in the CNS and peripheral nervous system of mice (Biffi et al., 2004). 
In mice affected by metachromatic leukodystrophy, hematopoietic stem cells transduced ex 
vivo with the arylsulfatase A gene, resulted in full reconstitution of enzyme activity. 
Moreover, by this procedure functional deficits such as motor conduction impairment and 
delayed learning could be prevented (Biffi et al., 2004). Similar results have been reported by 
Matzner and Gieselmann (2005).  
Although gene therapy studies performed in animal models are rather promising, many 
important issues regarding safety and efficacy of this therapeutic strategy need to be 
addressed before clinical trials can be initiated. To achieve high enzyme activity a high level 
of transgene expression by hematopoietic stem cells might be required, and the integration 
of a large amount of vectors increases the risk of integrated-dependent adverse events. The 
occurrence of adverse events in patients with an X-linked severe combined 
immunodeficiency who were treated by gene therapy led to major attention regarding 
mutagenesis and leukemogenesis related to retroviral integration (Hacein-Bey-Abina et al., 
2003). Furthermore, retroviral and lentiviral vectors tend to be integrated close to expressed 
genes, thus increasing the likelihood of transcriptional interference between the vector and 
flanking endogeneous genes (De Palma et al., 2005). This interference may lead to silencing 
of the endogeneous gene targeted by the integration and also to transcriptional deregulation 
of the endogenous genes that are located near the integration site. Such interference may be 
avoided by using late-generation lentiviral vectors that are self-inactivating with 
transcriptionally inactive long terminal repeats (LTRs) on transduction, which express the 
transgene from an internal promoter of choice. Furthermore, the risk of insertional 
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mutagenesis by retroviral and lentiviral vectors may be different due to their biological 
differences.  Table 1 summarises the neuronopathic LSDs for which hematopoietic stem cell 
therapy (HSCT) is considered to be either a first line or optional treatment for preventing or 
arresting neurocognitive decline. Additionally, three clinical trials are underway to assess 
the efficacy of gene-modified HSCT in MPS II, MPS VII and MLD (Table 1). 
Direct engraftment of exogenous cells into the CNS is a therapeutic strategy first examined 20 
years ago, however, to our knowledge, only one clinical trial has been completed using this 
treatment method (www.clinicaltrials.gov.; NCT00337636), in infantile and late-infantile 
neuronal ceroid lipofuscinosis patients aged 18 months to 12 years using unmodified human-
derived neural stem cells (Tamaki et al., 2009). Another clinical trial using the same cell type is 
in the recruitment phase (NCT01238315) and younger patients will be enrolled this time (6 
months to 6 years of age). Whilst there is pre-clinical evidence from the mid-1990 s to support 
the potential success of this approach, e.g. Lacorazza et al. (1996; Tay-Sachs mice); Snyder et al. 
(1995; MPS VII), problems such as the invasive nature of the treatment, ethical debates 
regarding some sources of donor cells and the need for widespread replacement of lysosomal 
proteins in brain, have hampered the translation of this therapeutic approach. 
 
 
Table 1. Summary of human clinical trials investigating central nervous system (CNS)-
directed gene therapy or haematopoietic stem cell (HSC) approaches for treatment of CNS 
disease in lysosomal storage diseases (from 
http://www.wiley.com/legacy/wileychi/genmed/clinical/, www.clinicaltrials.gov, 
Hemsley & Hopwood, 2011) 
Disease Clinical trial 
stage 
Vector Delivery method Contacts and trial details 
Gene Therapy 
LINCL Phase I, open AAV2 Intracerebral injection Ronald Crystal, New York, 
USA US-0619, NCT 
00151216 (Souweidane et 
al., 2010) 
LINCL Phase I, open AAV-rh10 Intracerebral injection Ronald Crystal, New York, 
USA US-0977 NCT 
01161576 
HSC Therapy 
MPS I Routine clinical 
use 
Nil i.v. infusion of cells harvested 
from compatible donor 




Clinical Nil i.v. infusion See Boelens et al. (2010) 
Fucosidosis Clinical Nil i.v. infusion See Boelens et al. (2010) 
MLD late 
onset 
Clinical Nil i.v. infusion See Boelens et al. (2010) 
Krabbe 
disease 
Clinical Nil i.v. infusion See Boelens et al. (2010) 
Gene-modified cell therapy 
MPS II Phase I/II, 
closed 
Retrovirus Ex vivo modification of 
autologous HSC, i.v. infusion 
L. Lashford, Manchester, 
UK UK-0011 
MPS VII Phase I, open Lentivirus Ex vivo modification of 
autologous HSC, i.v. infusion 
Mark Sands, St Louis, USA 
US-0758 
MLD Phase I/II, open Lentivirus Ex vivo modification of 
autologous HSC, i.v. infusion 
Alessandra Biffi, Milan, 
Italy IT-0019 
MPS I Phase I, open Retrovirus Intraperitoneal delivery of 
autologous exogenously modified 
fibroblasts 
Alain Fischer, INSERM 
Paris, France FR-0005 
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2.4 Chaperone therapy  
Several mutations lead to a wrong protein folding, causing instability and a decreased 
enzymatic activity, or a default in the routing of proteins. Small molecules chaperones with 
a low molecular weight can be used in these cases. These molecules can cross the blood 
brain barrier and can easily diffuse through the tissues, underlining their interest in the mild 
forms of lysosomal storage diseases (LDSs) with neurological involvement.  
Two different types of chaperones exist: the chemical chaperones, which are non specific 
molecules which stabilize mutant proteins misfolded in the ER (Sato et al., 1996), and 
pharmacological chaperones, which are enzyme-specific substrates analogues, and which 
stabilize the proteins during their synthesis. In the last few years it has been found that 
imino-sugars do not only act as enzyme inhibitors, but also have an effect as so-called 
chaperones. Chaperones are a part of a cell system that has the task to control the quality of 
newly synthesized proteins. This machinery, which involves the ubiquitin system and 
proteosomes, eliminates misfolded or unstable mutant proteins. Under physiological 
conditions, chaperones restore the native conformation of misfolded proteins. It has been 
estimated that up to 30% of normal proteins do not become functionally active, but in 
contrast are misfolded and consequently aggregate and are rapidly (within minutes) 
degraded by the cell’s quality control machinery (Bernier et al., 2004). In genetic disorders, 
certain missense mutations and some small in-frame deletions may cause polypeptide 
misfolding, but may not (or only slightly) impair the functionally essential domains of the 
mutant protein (the active site, receptor-binding site, etc (see Figure 1).  
 
Fig. 1. A: Normally, the lysosomal enzymes are synthesized in the endoplasmic reticulum 
(ER) and transport to the Golgi apparatus, where they receive the mannose-6-phosphate 
marker that is essential for receptor-mediated sorting into the lysosomes. B: The mutant 
enzyme is misfolded and retained in the ER, enzyme activity is lacking in the lysosome. C: 
N-butyldeoxynojirimycin increases the stability of the mutant enzyme that now is able to 
enter the Golgi apparatus and- after binding the mannose-6-phosphate receptor- becomes 
active within the lysosome (from Beck, 2007). 
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Pharmacological chaperones, such as substrate analogues, may facilitate the stabilization of 
misfolded proteins and imino-sugars such as deoxynojirimycin-analogues function as 
chaperones. The effect of N-(n-nonyl)deoxynojirimycin (NN-DNJ) on fibroblasts from a 
Gaucher patient who had the common N370S mutation was investigated by Sawkar et al. 
(2002). The addition of sub-inhibitory concentrations of NN-DNJ to the cultured cells 
resulted in a twofold increase in the activity of beta-glucocerebrosidase. The NN-DNJ 
chaperone also increased wild-type beta-glucocerebrosidase activity, but not that of the 
L444P mutation, which in general is associated with neurological involvement.  
In GM2-gangliosidoses (Tay–Sachs and Sandhoff disease), the chronic adult forms have an 
enzyme activity of approximately 5%, and there are healthy individuals who exhibit only 
10% of normal levels. Considering that in late-onset variants of GM2-gangliosidoses almost 
all disease-associated missense mutations do not affect the active site but lead to misfolding 
of the mutated protein, the influence of several known hexosaminidase inhibitors, such as 
N-Acetyl-galactosamine (GalNAc), Deoxynojirimycin (DNJ), Castanospermine (CAS) or N-
Acetyl-glucosamine-thiazoline (NGT), was studied (Tropak et al., 2004). By the addition of 
these inhibitors to cultured fibroblasts from an adult Tay–Sachs patient who carried the 
mutation G269S, an increase in the activity levels of intralysosomal hexosaminidase A well 
above the critical 10% of normal levels could be achieved. A similar effect was observed in 
fibroblasts from an adult Sandhoff patient (Tropak et al., 2004).  
Other studies are in progress to identify new chemical or pharmacological chaperones for 
LSDs (Ficko-Blean et al., 2008; Feldhammer et al., 2009; Valenzano et al., 2011). In summary, 
small molecule chemical chaperones may be therapeutically useful for various lysosomal 
storage disorders caused by mutant but yet catalytically active enzymes.  
3. Therapeutic strategy focused on reducing substrate production and/or 
accumulation 
3.1 Substrate reduction therapy  
Substrate reduction therapy represents a novel approach for the treatment of 
glycosphingolipidoses. Whereas enzyme replacement therapy is aimed at removal of 
storage material accumulating within the lysosome, the principle of substrate reduction 
therapy is to partially inhibit the biosynthetic cycle, in order to reduce substrate influx into 
the catabolically compromised lysosome. The concept that an inhibition of ceramide 
glucosyltransferase, which represents the key enzyme in glycosphingolipid (GSL) synthesis, 
could lead to reduction in GSL concentration, was originally proposed by Radin (1996). As 
best candidates for ceramide glucosyltransferase inhibition, emerged the imino-sugars that 
were already known to reduce the activity of the enzyme beta-glucosidase.  
First clinical trials allowed the assessment for efficacy in type I Gaucher disease (Cox et al., 
2000). In this study, 28 adult Gaucher patients who were unable or unwilling to receive 
enzyme replacement therapy were treated with N-butyldeoxynojirimycin (100 mg three 
times daily). At 12 months, mean liver and spleen volumes were significantly lowered by 12 
and 19%, respectively. Hematological parameters showed a slight improvement. The most 
frequent adverse effect was diarrhea, which occurred in 79% of patients shortly after the 
start of treatment. Although the occurrence of tremor and peripheral neuropathy in patients 
on N-butyldeoxynojirimycin and the development of cognitive dysfunction in a single case 
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raised a number of issues regarding safety of this drug (Pastores and Barnett, 2003), the 
proof of principle allowed for further clinical studies to evaluate low dose administration 
(Heitner et al., 2002) and long-term treatment (Elstein et al., 2004). In the latter extension 
study statistically significant improvement in all major efficacy endpoints were achieved 
indicating that treatment with N-butyldeoxynojirimycin was increasingly effective with 
time. In this trial no new case of peripheral neuropathy was reported and diarrhea and 
weight loss decreased. N-butyldeoxynojirimycin's action on glucosylceramide synthesis is 
illustrated in Figure 2. 
 
Fig. 2. N-butyldeoxynojirimycin inhibits the synthesis of glucosylceramide, the precursor of 
all glucosphingolipids (from Beck, 2007). 
In 2003 an independent international advisory group made a statement regarding the role of 
N-butyldeoxynojirimycin in the treatment of type I Gaucher disease (Cox et al., 2003). The 
advisory council considered the following patient categories to be eligible for such 
treatment: (i) adult patients with mild or moderate symptomatic Gaucher disease who are 
unwilling or unable to receive or to continue ERT, and (ii) patients with persistent signs of 
disabling disease activity despite maximal enzyme dosing. In these patients the drug may be 
applied in combination with ERT. 
As glucosylceramide represents the precursor of several glycosphingolipids such as 
globosides and gangliosides, N-butyldeoxynojirimycin was also considered as a treatment 
option for patients with GM1- or GM2-gangliosidoses. This assumption is also supported by 
the fact that this drug is a small molecule that is able to cross the blood–brain barrier 
(Lachmann et al., 2004). Jeyakumar et al. (1999) performed an experiment in a mouse model 
of Sandhoff disease (0 variant of GM2- gangliosidosis). Mice treated with this drug showed 
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delayed symptom onset, reduced storage in peripheral tissues and in the brain, and 
increased life expectancy. Based on these positive experimental data, Bembi et al. (2006) 
investigated the clinical efficacy of N-butyldeoxynojirimycin in two patients with infantile 
Tay-Sachs disease (B variant of GM2-gangliosidosis). However, the enzyme inhibitor could 
not slow down the progressive clinical deterioration.  
Niemann–Pick disease type C (NPC) is a genetic lipid storage disorder mostly caused by 
mutations in NPC1, a membrane protein involved in endosomal-lysosomal transport of 
lipids. In the brains of NPC patients, the gangliosides are the major storage lipids and there 
is evidence from the NPC mouse model that accumulation of gangliosides rather than of 
cholesterol leads to cellular dysfunction in neural tissue (Zervas et al., 2001). To evaluate this 
hypothesis, NPC mice were treated with N-butyldeoxynojirimycin (Miglustat, Actelion). 
Treatment resulted in delayed onset of neurological dysfunction, increased life span and 
reduction of ganglioside accumulation in the brains of the animals. N-
butyldeoxynojirimycin was used for the first time in a patient with Niemann–Pick C disease 
type I in a study performed by Lachmann and co-workers (2004). The adult female received 
the drug at a dosage of 100 mg once daily. After several months of treatment a decrease in 
pathological lipid storage was seen in her peripheral blood lymphocytes. Her clinical 
condition remained stable (Lachmann et al., 2004). Several clinical trials have since been 
conducted in humans using Miglustat, demonstrating mild clinical improvement or 
stabilization, with greater impact on earlier diagnosed populations. Miglustat is the only 
currently approved therapy for NPC disease and clearly slows disease progression with 
limited side effects (Wraith et al., 2009; Patterson et al., 2010; Galanaud et al., 2009; Patterson 
et al., 2007). 
3.2 Isoflavones-based therapy of MPS diseases 
More recently, the Wegrzyn’s team has demonstrated that treatment with the isoflavone 
genistein [4′, 5, 7-trihydroxyisoflavone or 5, 7-dihydroxy-3- (4-hydroxyphenyl)-4H-1-
benzopyran-4-one] (Figure3), impairs glycosaminoglycans synthesis and thus may represent 
an effective method of reducing GAG storage in MPS patient cells (Piotrowska et al., 2006). 
This inhibition has been proposed to be due to a genistein-mediated inhibition of kinase 
activity of the epidermal growth factor receptor (Piotrowska et al., 2006; Jakóbkiewicz-
Banecka et al., 2009). Malinowska et al. (2009) recently described significant reductions of 
accumulated heparan sulphate substrate in liver of a mouse model of MPS IIIB using the 
tyrosine kinase inhibitor genistein. The tyrosine kinase inhibitory effect of genistein most 
probably affects the expression of genes encoding enzymes necessary for GAG synthesis. 
Nevertheless, this remains to be clearly established, as well as the mechanism of action of 
other flavonoid compounds which appearing to mediate their effect via an alternative 
pathway (Kloska et al., 2011). 
Subsequent studies have indicated that genistein may be effective in treatment of mice 
suffering from MPS IIIB (one of four subtypes of MPS III) and MPS II, including 
improvement in CNS in short-term treatment of animals with the latter disease and 
complete correction of behavior in long-term treatment of animals with the former disease 
(Friso et al., 2010; Malinowska et al., 2009, 2010). In pilot clinical studies, it was 
demonstrated that the treatment of patients suffering from MPS IIIA and MPS IIIB with a 
genistein-rich isoflavone extract resulted in statistically important improvement of all tested 
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parameters (when mean values from all patients were compared), including cognitive 
functions, as assessed by using a special psychological test (Piotrowska et al., 2008). After a 
2-year follow-up of this pilot study, the results showed that, in 5 treated children, this 
genistein treatment might be interesting to improve cognitive functions and behavioral 
symptoms or at least stop their deterioration over a period of time (Piotrowska et al., 2011). 
The effects of genistein on neurological parameters in MPS animals and humans were 
assumed to be due to an ability of this isoflavone to cross the blood-brain-barrier, which was 
demonstrated previously (Tsai, 2005).  
 
Fig. 3. Isoflavone structure, numbering. Genistein (5-OH, 7-OH, 4'-OH) or daidzein (7-OH, 
4'-OH) are e. g. members of the isoflavone family. Isoflavone differs from flavone (2-phenyl-
4H-1-benzopyr-4-one) in location of the phenyl group 
This therapeutic approach is promising. However, it is also clear that further studies are 
necessary to optimize this procedure. For example, we have tested various isoflavones for 
their activities in correction of GAG lysosomal accumulation in MPS IIIA and MPS VII 
fibroblasts, and found that some of the tested compounds are as efficient as genistein in 
decreasing GAG storage in MPS cells, and that a combination of different compounds from 
this group may be more efficient than one single flavonoid (Arfi et al., 2010). Another study 
has shown the effects of other flavonoids (apigenin, daidzein, kaempferol and naringenin) 
on GAG synthesis (Kloska et al., 2011).  Indeed, the Wegrzyn’s team found that daidzein 
and kaempferol inhibited GAG synthesis significantly (Kloska et al., 2011). Moreover, these 
compounds were able to reduce lysosomal storage in MPS IIIA fibroblasts. Interestingly, 
although genistein is believed to inhibit GAG synthesis by blocking the tyrosine kinase 
activity of the epidermal growth factor receptor, they found that effects of other flavonoids 
were not due to this mechanism. Again, a combination of various flavonoids resulted in 
significantly more effective inhibition of GAG synthesis than the use of any of these 
compounds alone (Kloska et al., 2011). Altogether, these results suggest that combination of 
flavonoids can be considered as a method for improvement of efficiency of SRT for MPS III 
or other LSD. 
4. Complementary therapeutic strategies, based on downstream 
consequences of enzyme deficiency and substrate accumulation 
4.1 Anti-inflammatory molecules 
Neurodegeneration has been observed in several lysosomal diseases, but the relationship 
between substrate accumulation and neurological disorder remains unclear. Inflammation is 
known to be implicated in numerous neurodegenerative diseases, and has been recently 
well characterized in murine models of GM1/GM2 gangliosidoses (Myerowitz et al., 2002, 
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Jeyakumar et al., 2003), as well as in mouse models of Metachromatic Leukodystrophy (Hess 
et al., 1996), Niemann-Pick C disease (German et al., 2002), MPS I (Ohmi et al., 2003), MPS 
IIIB (Ohmi et al., 2003; Villani et al., 2007) and MPS IIIA (Fraldi et al., 2007). Moreover, our 
previous study on a mouse model of MPS VII showed an extensive upregulation of genes 
related to an inflammatory process dominated by activated microglia, astrogliosis and cell-
death, suggesting that inflammation might participate in neurodegeneration (Richard et al., 
2008). 
Therefore, targeting brain inflammation represents a potential clinical intervention strategy. 
Indeed, several studies have recently shown that anti-inflammatory treatments, using 
nonsteroidal anti-inflammatory drugs (NSAIDs) significantly slowed the clinical course of 
both Sandhoff and Niemann-Pick type C1 diseases (Jeyakumar et al., 2003; Jeyakumar et al., 
2004; Smith et al., 2009). It has also been shown by our group in the MPS IIIA mouse models, 
following-up several inflammation markers (Arfi et al., 2011). NSAID could also be 
combined with other therapies targeting the primary defect, aiming at additive or 
synergistic benefit. However, further studies are necessary to characterize and maybe 
correlate a potential clinical improvement to the molecular and biochemical effects observed 
in aspirin-treated mice (Jeyakumar et al., 2004; Smith et al., 2009). In addition, careful 
preclinical and clinical studies would be required to determine whether these findings 
extrapolate to the human disease.  
4.2 Anti-oxidative molecules 
A recent study by our group has evidenced a clear oxidative stress not only in MPS IIIA 
mouse brains, but also in MPS IIIA peripheral organs such as liver and spleen, as early as 6 
months of age (Arfi et al., 2011). Other studies previously highlighted ROS release and/or 
increased expression of components of the phagocyte NADPH oxidase in GM1 
gangliosidosis (Jeyakumar et al., 2003), MPS IIIB (Villani et al., 2007), MPS I (Reolon et al., 
2009) or Batten disease (Benedict et al., 2007). It is still not defined whether the previously 
reported and presently observed oxidative imbalance is triggered by lysosomal dysfunction 
(Butler and Bahr, 2006), by autophagy impairment as recently described in MPS IIIA and 
Multiple Sulfatase Deficiency (MSD) mouse models (Settembre et al., 2008), or is a 
secondary result from microglial activation. Nevertheless, it seems clear that these oxidative 
alterations may enhance damages in brain cells, and may contribute to cognitive impairment 
as well as neurodegeneration through decline in synaptic integrity.  
Beyond NSAID treatment, we have tested an anti-oxidant treatment (vitamin C) alone or in 
combination with aspirin in the MPS IIIA mouse model, but this treatment failed to show 
much benefit, neither at the molecular level nor at the cellular level (Arfi et al., 2011). Similar 
results have recently been observed with various antioxidant treatments in other LSD 
models, such as in the NPC1 mouse (Bascunan-Castillo et al., 2004; Smith et al., 2009). 
However, some caution is required in interpreting these data, as we tested only one time 
point looking at biochemical and molecular changes in brain, liver and spleen tissues. In the 
Sandhoff mouse, anti-oxidant therapy with vitamin C did provide a modest but significant 
clinical improvement as a monotherapy (Jeyakumar et al., 2004). Future studies could be 
performed using more powerful anti-oxidant strategies with compounds that efficiently 
cross the blood-brain barrier (Agus et al., 1997). 
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5. Conclusions and perspectives 
After considerable in vitro and in vivo testing of a very large number of therapeutic 
candidates, a number of clinical trials are now in progress for many neuropathic lysosomal 
storage diseases. Clearly, one therapy approach will not, and indeed does not fit all 
disorders but the commonality of some pathology (e.g. neuroinflammation) and the general 
applicability of some strategies should encourage early stage similar studies to shorten the 
time between initial testing and human trials, if at all possible. Combination therapy 
strategies are supported by in vivo animal model data and are likely to be the way of the 
future. Well characterised animal models that are faithful to the human disorder they 
parallel are absolutely essential for timely and cogent progression through the research 
pipeline. Testing of therapies in animal models at various disease stages, i.e. pre and post-
symptomatic in addition to late-stage disease, will enable to thoroughly understand the 
potential benefits and limitations of each therapeutic approach. 
In parallel to the therapeutic research axis, the identification of new biomarkers is also 
crucial. Indeed, biomarkers are analytical tools that reflect the presence of a given disease 
(diagnostic biomarker). Biomarkers may also have prognostic significance for disease 
outcome, and emphasis is placed on those quantitative biomarkers which correlate with the 
clinical manifestations of the disease that affect quality of life, risk of complications or 
survival (surrogate biomarkers). Surrogate biomarkers have a critical role in the 
pharmaceutical licensing process and the monitoring of disease after the introduction of 
approved treatments. Surrogate biomarkers have special significance in the monitoring of 
treatments for rare diseases, where the small number of patients and heterogeneous 
expression of their underlying pathology pose formidable difficulties for direct study and 
where costly treatment must be justified in terms of efficacy. Much work will be needed to 
discover putative biomarkers and develop them for clinical use. More work generally will 
be needed across the fields of medicine to understand lysosomal diseases and their critical 
consequences on patients' life and quality of life. 
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